Cancer treatment using extracellular secretion

WO2026176598A1PCT designated stage Publication Date: 2026-08-27GENERAL INC ASSOCIATION ADVALIFE SCIENCE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2025/005920
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-02-20
Publication Date
2026-08-27

Smart Images

  • Figure JPOXMLDOC01-APPB-C000001
    Figure JPOXMLDOC01-APPB-C000001
  • Figure JPOXMLDOC01-APPB-C000002
    Figure JPOXMLDOC01-APPB-C000002
  • Figure JPOXMLDOC01-APPB-C000003
    Figure JPOXMLDOC01-APPB-C000003
Patent Text Reader

Abstract

The present disclosure provides a cancer treatment that uses an extracellular secretion. In a specific embodiment, the present disclosure provides a cancer treatment that uses a combination of an extracellular secretion and an ascorbic acid component. The present disclosure provides uses, methods, combinations, or compositions for the treatment of cancer. In one embodiment, the cancer may be breast cancer (including triple-negative breast cancer lacking estrogen receptors, progesterone receptors, and HER2). The subject to be treated includes mammals such as humans, mice, rats, cats, and dogs.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A combination for treating cancer, containing extracellular secretions and ascorbic acid components.

2. The combination according to claim 1, wherein the cancer includes breast cancer or cervical cancer.

3. The combination according to claim 1, wherein the cancer includes breast cancer.

4. The combination according to claim 1, wherein the cancer includes triple-negative breast cancer.

5. The combination according to claim 1 for treating a human or non-human mammal.

6. The combination according to claim 1, comprising the ascorbic acid component in a ratio of about 3 to about 100 mg per 1 mL of the extracellular secretion.

7. The combination according to claim 1, wherein the ascorbic acid component is ascorbic acid or a derivative thereof or a salt thereof.

8. The combination according to claim 1, wherein the extracellular secretion is obtained from the culture supernatant of mesenchymal stem cells.

9. The extracellular secretion is approximately 6 × 10 １０ The combination according to claim 1, comprising small extracellular vesicles (sEVs) of a certain size per mL or more.

10. A composition for treating cancer, comprising an extracellular secretion, characterized in that it is used in combination with an ascorbic acid component.

11. A composition for treating cancer, comprising an ascorbic acid component, characterized in that it is used in combination with an extracellular secretion.